ProCE Banner Activity

SWAP: Adding or Switching to PegIFN Improves Response in Patients With Chronic Hepatitis B on Long-Term NA Therapy

Slideset Download
Conference Coverage
Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.

Released: November 16, 2019

Expiration: November 14, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Intercept Pharmaceuticals